ArticleWorld journal of surgical oncology2026
MiR-4725-3p acts as an oncogene and prognostic biomarker in hepatocellular carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is an aggressive malignant neoplasm with high incidence and dismal prognostic outcomes. PURPOSE: This study sought to validate the prognostic significance of miR-4725-3p in HCC and the possible molecular mechanism.
methodsA total of 117 HCC patients were stratified into two groups according to the median expression level of miR-4725-3p. Following a 5-year follow-up with death as the end event, a Kaplan-Meier curve was drawn. The potential risk factors for poor prognosis were evaluated using Cox regression analysis. Cell Counting Kit-8 (CCK-8) and Transwell assay were employed to assess the role of miR-4725-3p silencing on Huh-7 and Hep3B cells viability and migration. Downstream target genes of miR-4725-3p were predicted, and a dual-luciferase assay was conducted to verify the interaction.
resultsMiR-4725-3p was significantly upregulated in HCC tissue and cell line. Survival analysis showed that high miR-4725-3p expression was associated with poor prognosis in HCC patients (log-rank P = 0.006). At the cellular level, silencing miR-4725-3p significantly suppressed the viability and migration of Huh-7 and Hep3B cells. Mechanistically, activating transcription factor 5 (ATF5) was identified as a direct target of miR-4725-3p. ATF5 was downregulated in HCC tissue and cells.
conclusionThe results of this study revealed that miR-4725-3p serves as a promising prognostic biomarker for HCC, and its oncogenic role in promoting HCC cell viability and migration may be mediated, at least in part, via the negative regulation of ATF5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.